Site-Specific Enzymatic Radiofluorination of Biomolecules: From Current Methodologies to Emerging Opportunities
Year: 2026
Type: article
Abstract: The recent expansion of recombinant biomolecules as diagnostic and therapeutic agents has created a strong need for mild, site-specific, and universally applicable methods to radiolabel them for positron emission tomography (PET). Fluorine-18 is one of the most widely used radionuclides for PET because it combines a clinically practical half-life, high positron intensity with low mean energy, and a non-metallic footprint in the label. However, the conditions necessary for efficient nucleophilic fluorine-18 radiolabelingbasic, anhydrous media, elevated temperature, and aprotic solventsare poorly compatible with sensitive biomolecules. Therefore, prosthetic group labeling with subsequent conjugation, both site-specific and non-site-specific, and aluminum-[18F]fluoride (Al[18F]F2+) chelation have become essential workarounds. Depending on the radiolabeling site, this can yield heterogeneous products, with impaired tracer target binding and pharmacokinetics. Enzymatic ligation offers a complementary strategy, with radiofluorination done on a robust small-molecule or peptide substrate, and subsequently, an enzyme catalyzes a mild and site-specific conjugation to a genetically encoded recognition motif on the target. This ensures that each step proceeds under its own optimal conditions. This review evaluates the current state of enzymatic and chemoenzymatic radiofluorination of biomolecules, from the early fluorinase work to recent advances with lipoic acid ligase (LplA), peptide asparaginyl ligase, and sortase A (SrtA). It further reviews enzymes and techniques that could extend this toolbox. The field is still emerging, but available evidence suggests that enzyme-mediated radiofluorination can occupy a niche between classical prosthetic-group radiochemistry and kit-like radiometal labeling, especially for fragile recombinant biomolecules whose radiolabeling with fluorine-18 is currently a challenge.
Source: Bioconjugate Chemistry
Institutions: University of Helsinki, Vrije Universiteit Brussel
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
Awards: VYPER — Viola Yedoensis Peptide asparagine ligase (VyPAL) Enzyme-mediated generation of Radiotheranostics, Development of automated enzyme-mediated bioconjugations as a technology to produce smallprotein-based radiopharmaceu, G3591979500, G3693470553, Development of a novel chemoenzymatic technology to radiofluorinate Nanobodies
OpenAlex ID: W7234198938
